Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 4/20 | 0.48 |
| ▸ | NAAA | Q02083 | 1/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19347407 | 0.90 | TSHR (0.49) | HTTTSHRHPGDHCRTR1KDM4E | |
| SCHEMBL23169262 | 0.84 | TSHR (0.68) | HTTTSHRHPGDNAAAHCRTR1 | |
| SCHEMBL13164043 | 0.81 | HPGD (0.68) | HTTTSHRHPGDKDM4ESMN1; SMN2 | |
| SCHEMBL30843288 | 0.80 | HTT (0.65) | HTTTSHRHPGDNAAAHCRTR1 | |
| SCHEMBL1754800 | 0.79 | TSHR (0.67) | HTTTSHRHPGDNAAAKDM4E | |
| SCHEMBL28850411 | 0.79 | HTT (0.54) | HTTTSHRHPGDNAAAHCRTR1 | |
| SCHEMBL23992489 | 0.79 | HTT (0.59) | HTTTSHRHPGDKDM4EHSD17B10 | |
| SCHEMBL4744541 | 0.77 | TSHR (0.43) | HTTTSHRHPGDHCRTR1SMN1; SMN2 | |
| SCHEMBL18285118 | 0.74 | ALOX5 (0.78) | HTTTSHRHPGDNAAAHSD17B10 | |
| SCHEMBL8515238 | 0.74 | ALDH1A1 (0.57) | HTTTSHRHPGDKDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10765110-B2 | Agent for preserving biological component | Tabata, Yasuhiko (JP) | 2020-09-08 | — | — | US | disclosed |
| US-20170311586-A1 | AGENT FOR PRESERVING BIOLOGICAL COMPONENT, AND METHOD FOR RECOVERING BIOLOGICAL COMPONENT | Tabata, Yasuhiko (JP) | 2017-11-02 | — | — | US | disclosed |
| EP-3219787-A1 | AGENT FOR PRESERVING BIOLOGICAL COMPONENT, AND METHOD FOR RECOVERING BIOLOGICAL COMPONENT | Denka Company Limited (JP) | 2017-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170311586-A1 | AGENT FOR PRESERVING BIOLOGICAL COMPONENT, AND METHOD FOR RECOVERING BIOLOGICAL COMPONENT | CD44, HPSE, PLOD3 | HTT 325/4885TSHR 2712/4885HPGD 464/4885 |
| US-10765110-B2 | Agent for preserving biological component | CD44, MUC1, PLOD3 | HTT 438/4885TSHR 2814/4885HPGD 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.